AFMD: שווי חברה לרווח נקי affimed.com

Serving as a valuation tool, the Affimed (AFMD) price chart demonstrates a P/E multiple of 0.00, with the business generating revenue from the development of anti-tumor agents and licensing royalties for access to ROCK technology. The firm's environmental policy focuses on modernizing treatment systems and conserving water resources within its laboratories. A competitive advantage is secured through exclusive patents for bispecific antibodies and a strategic alliance with the market's largest behemoths.

Affimed is an oncology biotech whose viability relies on external financing and grants in the absence of its own sales. The P/E ratio relates current market capitalization to net profit, measuring the payback period for investments. This indicator allows for an assessment of market expectations regarding the future profitability of the business. Abnormal values signal either inflated hopes or a deep profit deficit. By analyzing the price-to-earnings ratio trend, an investor can see the real cost of each unit of income.